Ultrasonographic Fetal Nuchal Translucency Measurements and Cytogenetic Outcomes
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.3689 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Kara Bellai-Dussault und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Down Syndrome, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR.
Abstract (Originalsprache)
Importance Ultrasonographic measurement of fetal nuchal translucency is used in prenatal screening for trisomies 21 and 18 and other conditions. A cutoff of 3.5 mm or greater is commonly used to offer follow-up investigations, such as prenatal cell-free DNA (cfDNA) screening or cytogenetic testing. Recent studies showed a possible association with chromosomal anomalies for levels less than 3.5 mm, but extant evidence has limitations.
Objective
To evaluate the association between different nuchal translucency measurements and cytogenetic outcomes on a population level. Design, Setting, and Participants This population-based retrospective cohort study used data from the Better Outcomes Registry & Network, the perinatal registry for Ontario, Canada. All singleton pregnancies with an estimated date of delivery from September 1, 2016, to March 31, 2021, were included. Data were analyzed from March 17 to August 14, 2023. Exposures Nuchal translucency measurements were identified through multiple-marker screening results. Main Outcomes and Measures Chromosomal anomalies were identified through all Ontario laboratory-generated prenatal and postnatal cytogenetic tests. Cytogenetic testing results, supplemented with information from cfDNA screening and clinical examination at birth, were used to identify pregnancies without chromosomal anomalies. Multivariable modified Poisson regression with robust variance estimation and adjustment for gestational age was used to compare cytogenetic outcomes for pregnancies with varying nuchal translucency measurement categories and a reference group with nuchal translucency less than 2.0 mm.
Results
Of 414 268 pregnancies included in the study (mean [SD] maternal age at estimated delivery date, 31.5 [4.7] years), 359 807 (86.9%) had a nuchal translucency less than 2.0 mm; the prevalence of chromosomal anomalies in this group was 0.5%. An increased risk of chromosomal anomalies was associated with increasing nuchal translucency measurements, with an adjusted risk ratio (ARR) of 20.33 (95% CI, 17.58-23.52) and adjusted risk difference (ARD) of 9.94% (95% CI, 8.49%-11.39%) for pregnancies with measurements of 3.0 to less than 3.5 mm. The ARR was 4.97 (95% CI, 3.45-7.17) and the ARD was 1.40% (95% CI, 0.77%-2.04%) when restricted to chromosomal anomalies beyond the commonly screened aneuploidies (excluding trisomies 21, 18, and 13 and sex chromosome aneuploidies). Conclusions and Relevance In this cohort study of 414 268 singleton pregnancies, those with nuchal translucency measurements less than 2.0 mm were at the lowest risk of chromosomal anomalies. Risk increased with increasing measurements, including measurements less than 3.5 mm and anomalies not routinely screened by many prenatal genetic screening programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
- Prenatal Screening Ontario for Better Outcomes Registry & Network Ontario, Ottawa, Canada.
- Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.
- DAN Women & Babies Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
- Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, Canada.
Förderung
- CIHR
Zitieren
APA
Bellai-Dussault, K., Dougan, S. D., Fell, D. B., Little, J., Meng, L., Okun, N., Walker, M. C., Armour, C. M., & Potter, B. K. (2024). Ultrasonographic Fetal Nuchal Translucency Measurements and Cytogenetic Outcomes. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.3689
Vancouver
Bellai-Dussault K, Dougan SD, Fell DB, Little J, Meng L, Okun N, et al. Ultrasonographic Fetal Nuchal Translucency Measurements and Cytogenetic Outcomes. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.3689
BibTeX
@article{BellaiDussault2024,
author = {Bellai-Dussault, Kara and Dougan, Shelley D and Fell, Deshayne B and Little, Julian and Meng, Lynn and Okun, Nan and Walker, Mark C and Armour, Christine M and Potter, Beth K},
title = {Ultrasonographic Fetal Nuchal Translucency Measurements and Cytogenetic Outcomes},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.3689}
}
EUVIMED